Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Johnson & Johnson    JNJ

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Johnson & Johnson : Fundsmith LLP Has $449,379,000 Stake in Johnson & Johnson

share with twitter share with LinkedIn share with facebook
share via e-mail
0
11/16/2016 | 11:52am CEST

Fundsmith LLP increased its position in Johnson & Johnson (NYSE:JNJ) by 24.1% during the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 3,704,693 shares of the companys stock after buying an additional 719,532 shares during the period. Johnson & Johnson comprises approximately 7.1% of Fundsmith LLPs portfolio, making the stock its 5th largest position. Fundsmith LLP owned approximately 0.14% of Johnson & Johnson worth $449,379,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the company. Americafirst Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth $101,000. Tuttle Tactical Management LLC acquired a new position in Johnson & Johnson during the second quarter valued at $103,000. Lenox Wealth Management Inc. boosted its position in Johnson & Johnson by 24.3% in the second quarter. Lenox Wealth Management Inc. now owns 972 shares of the companys stock valued at $118,000 after buying an additional 190 shares in the last quarter. Thomas J. Herzfeld Advisors Inc. boosted its position in Johnson & Johnson by 221.2% in the second quarter. Thomas J. Herzfeld Advisors Inc. now owns 1,002 shares of the companys stock valued at $122,000 after buying an additional 690 shares in the last quarter. Finally, NCM Capital Management Group Inc. acquired a new position in Johnson & Johnson during the second quarter valued at $127,000. 65.35% of the stock is owned by institutional investors.

Johnson & Johnson (NYSE:JNJ) opened at 118.61 on Monday. Johnson & Johnson has a one year low of $94.28 and a one year high of $126.07. The company has a market cap of $322.68 billion, a PE ratio of 20.82 and a beta of 0.75. The stock has a 50 day moving average price of $117.08 and a 200 day moving average price of $118.16.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 18th. The company reported $1.68 earnings per share for the quarter, beating the consensus estimate of $1.66 by $0.02. Johnson & Johnson had a net margin of 22.03% and a return on equity of 25.30%. The firm had revenue of $17.80 billion for the quarter, compared to analyst estimates of $17.71 billion. During the same quarter in the prior year, the business earned $1.49 earnings per share. The businesss quarterly revenue was up 4.2% compared to the same quarter last year. On average, equities analysts anticipate that Johnson & Johnson will post $6.72 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 6th. Stockholders of record on Tuesday, November 22nd will be issued a dividend of $0.80 per share. The ex-dividend date of this dividend is Friday, November 18th. This represents a $3.20 annualized dividend and a dividend yield of 2.70%. This is a positive change from Johnson & Johnsons previous quarterly dividend of $0.29. Johnson & Johnsons dividend payout ratio is currently 56.64%.

Several equities analysts recently weighed in on the company. RBC Capital Markets reissued an outperform rating and set a $133.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Leerink Swann reissued an outperform rating and set a $140.00 price objective (up previously from $125.00) on shares of Johnson & Johnson in a research report on Wednesday, July 20th. BMO Capital Markets reissued an outperform rating and set a $132.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, July 20th. Royal Bank Of Canada boosted their price objective on Johnson & Johnson from $125.00 to $133.00 and gave the stock an outperform rating in a research report on Wednesday, July 20th. Finally, Deutsche Bank AG restated a hold rating and set a $142.00 price target (up from $125.00) on shares of Johnson & Johnson in a research note on Thursday, July 21st. Two analysts have rated the stock with a sell rating, twelve have issued a hold rating and nine have assigned a buy rating to the companys stock. Johnson & Johnson has an average rating of Hold and an average target price of $120.79.

In related news, Director Charles Prince acquired 875 shares of the companys stock in a transaction dated Friday, October 21st. The shares were purchased at an average price of $114.11 per share, for a total transaction of $99,846.25. Following the completion of the acquisition, the director now owns 26,520 shares of the companys stock, valued at $3,026,197.20. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Insiders own 0.11% of the companys stock.

(c) 2016 Cihan News Agency. All right reserved. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on JOHNSON & JOHNSON
02:46a JOHNSON & JOHNSON : Ministry of Health and Prevention launches programme for ear..
10/22 JOHNSON & JOHNSON : Briefly
10/21 JOHNSON & JOHNSON : California judge tosses $417 million talc cancer verdict aga..
10/21 JOHNSON & JOHNSON : Judge throws out another talc verdict against Johnson & John..
10/21 JOHNSON & JOHNSON : Taiwan FDA finds problems with three lots of Acuvue contact ..
10/21 JOHNSON & JOHNSON : California judge tosses $417 mln talc cancer verdict against..
10/21 JOHNSON & JOHNSON : Judge tosses $417M award against Johnson & Johnson
10/21 JOHNSON & JOHNSON : Janssen receives two u.s. fda approvals for simponi aria® (g..
10/20 JOHNSON & JOHNSON : Ryan Tedder, Hamdi Ulukaya, Bulgari North America Honored at..
10/20 JOHNSON & JOHNSON : blames price cuts in India for poor show in knee-implant bus..
More news
News from SeekingAlpha
10/22 QUARTERLY REVIEW OF DIVGRO : Q3-2017
10/21 3 THINGS, OCTOBER 21, 2017 : Celgene's New Gamble, Pluristem Marches On ARS, Jan..
10/20 FDA OKs expanded uses for J&J's Simponi Aria
10/20 The Best DGI Stocks For Young Investors - October 1-12, 2017
10/20 YOUR DAILY PHARMA SCOOP : Johnson & Johnson's Mixed Signals, Celgene's Mongersen..
Financials ($)
Sales 2017 76 267 M
EBIT 2017 23 526 M
Net income 2017 15 953 M
Debt 2017 16 641 M
Yield 2017 2,35%
P/E ratio 2017 24,46
P/E ratio 2018 19,91
EV / Sales 2017 5,23x
EV / Sales 2018 4,84x
Capitalization 382 B
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | JNJ | US4781601046 | 4-Traders
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 144 $
Spread / Average Target 1,1%
EPS Revisions
Managers
NameTitle
Alex Gorsky Chairman & Chief Executive Officer
Dominic J. Caruso Chief Financial Officer & Vice President
Paulus Stoffels Chief Scientific Officer & Executive VP
Charles O. Prince Independent Director
William David Perez Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.50%226 404
PFIZER11.58%216 886
ROCHE HOLDING LTD.5.55%207 116
MERCK AND COMPANY7.88%174 223
AMGEN27.41%133 501